|
We asked 40 pharma leaders, do you agree that the potential fees charged by the EMA for pharmacovigilance activities are unjustifiably high?
| Yes |
76% |
| No |
18% |
| The wording of the fees is not clear |
6% |
 |
|
|
|
|
|
|
|
2 October, 2012
|
| In this Issue |
 |
Is the Worst of the Patent Cliff Behind Us?
In a bit of good news for pharma, Moody's Investors Service has upgraded its outlook for the global pharmaceutical industry to stable. The Moody's rating reflects expectations for fundamental business conditions in the industry over the next 12 to 18 months. Read more... |
Monsanto Rat Tumour Scare: A Wake-Up Call for the Industry?
The furore that burst across Brussels in late September over reported findings of tumours in rats fed with genetically modified maize may seem only tangentially related to the concerns of European pharmaceutical executives — but the significance of the debate it has generated should not be lost on anyone with an eye on the relationship between industry, health and the public at large. More... |
Open Innovation: What Does It Actually Mean?
There’s a lot of talk today about “open innovation” in business and research forums — but what exactly does it mean? How does open innovation as a concept apply to the pharma sector? Does it signal a change in the way pharma companies approach research and innovation? Roy F. Waldron reports. More... |
EMA Streamlines Working Parties
The European Medicines Agency (EMA) has abolished its Cell-based Product Working Party (CPWP) and Gene Therapy Working Party (GTWP), with the aim of improving efficiencies and optimizing the use of available expertise. More...
|
|
|
|
